Shares of Frequency Therapeutics FREQ surged 77.48% on Friday, after management announced that the company entered into a definitive agreement with RNA editing company, Korro Bio, to merge in an ...

Merger to create a Nasdaq-listed genetic medicines company focused on advancing Korro Bio’s wholly owned portfolio of RNA editing programs Lead program is a disease modifying therapy for patients with ...

(RTTNews) - Korro Bio, Inc., an RNA editing firm, and Frequency Therapeutics, Inc. (FREQ), announced on Friday that they have signed a deal to combine the two firms in an all-stock transaction. The ...

Merger aims to advance RNA editing programs. Korro Bio, a ribonucleic (RNA) editing organization, and Frequency Therapeutics Inc., have announced plans to merge into one company as part of an ...

A pending reverse merger with troubled Frequency Therapeutics is giving new meaning to Korro Bio’s slogan, “Edit the message. Rewrite the future.” For Korro, a developer of RNA-edited therapies, the ...

Funds multiple potentially value-creating milestones, including advancing its lead product candidate in Alpha-1 antitrypsin deficiency (AATD) through a clinical trial Shares to trade on Nasdaq under ...

Under the merger agreement's terms, stockholders of Korro Bio will receive newly issued shares of Frequency Therapeutics. Frequency Therapeutics has discontinued developing its remyelination program ...

Venture-backed Korro Bio of Cambridge said Friday it will absorb financially struggling Frequency Therapeutics through a reverse merger in which Korro will take over Frequency’s public stock listing ...

CAMBRIDGE & LEXINGTON, Mass.--(BUSINESS WIRE)--Korro Bio, Inc., a leading RNA editing company focused on the discovery and development of novel genetic medicines, and Frequency Therapeutics, Inc.

CAMBRIDGE & LEXINGTON, Mass., July 14, 2023--Korro Bio, Inc., a leading RNA editing company focused on the discovery and development of novel genetic medicines, and Frequency Therapeutics, Inc.